J. Paul DeYoung

TL;DR: GRACE risk score is a valid and powerful predictor of adverse outcomes across the wide range of Canadian patients with ACS and its excellent discrimination is maintained despite advances in management over time and is evident in all patient subgroups.

TL;DR: Despite the temporal increase in the use of invasive cardiac procedures, they remain paradoxically targeted toward low-risk patients with NSTE-ACS in contemporary practice, and this treatment-risk paradox needs to be further addressed to maximize the benefits of invasive therapies in Canada.

TL;DR: Although early use of clopidogrel therapy has increased over time across the spectrum of ACS, a significant proportion of eligible patients still do not receive this evidence-based therapy and there is a need to optimize the use of proven antiplatelet therapies to improve clinical outcome.

TL;DR: Over the last decade, NSTE-ACS patients with diabetes continue to be treated more conservatively, despite evidence that they would derive similar or even greater benefits from aggressive treatment, and this underutilization of evidence-based therapies among diabetic patients with NsteamACS in the "real world" may partly explain their worse outcome.

TL;DR: The GRACE RS is a valid predictor of in-hospital mortality for both men and women with ACS and the lack of interaction between sex and RS components suggests that sex-based modification is not required.